Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vical has received $2.1 million cash payment from AnGes for costs associated with the ongoing Allovectin-7 Immunotherapeutic, for metastatic melanoma Phase III trial.
Subscribe to our email newsletter
The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment will be included in Vical’s year-end 2007 cash balances, consistent with the company’s guidance of a projected 2007 net cash burn of $27 million to $32 million.
Vical is conducting the trial in accordance with a special protocol assessment completed with the FDA.